Newly published report in Nature Reviews Drug Discovery that provides a comprehensive, independent analysis of the global landscape of cancer cell therapies, including all agents from preclinical to post-market stages.
Month-long awareness and education campaign in June highlighting breakthroughs in cancer treatment with immunotherapy and the urgent need for more research funding
On March 19-20 in California, the third Fortune Brainstorm HEALTH conference brought together renowned leaders from healthcare and related industries to provide insight into today’s most pressing challenges as well as how we might solve them.
Two leading non-profits combine efforts to accelerate cancer immunotherapy clinical trials for patients globally
Comprehensive immuno-oncology landscape analysis conducted by nonprofit Cancer Research Institute quantifies global development of immunotherapy and identifies opportunities to advance the field to improve patient care
Fight Colorectal Cancer (Fight CRC) and the Cancer Research Institute (CRI) are proud to announce “A Blueprint to Advance Colorectal Cancer Immunotherapies”
The Cancer Research Institute will give awards for scientific achievements in immunology and tumor immunology and immunotherapy to three accomplished research scientists at its 31st Annual Awards Dinner on November 14, 2017, in New York City.
Cancer Research Institute will recognize Genentech and Bruce Ratner for their contributions to medical research, patient care, or public education in the fields of cancer immunology and immunotherapy.
A collaborative campaign brings together the leading funder of immunotherapy research internationally with North America’s largest nonprofit dedicated to supporting Israeli cancer research
$400k grant to Johns Hopkins University School of Medicine investigator Cynthia Sears will carry out research aimed at improving effectiveness of immunotherapy in patients with colorectal cancer.
$1 million CRI Technology Impact Award will support UPENN investigator's development of microchip-based research models that mimic human cancer and immune cell interactions
CRI's 2017 Immunotherapy Patient Summit Series will travel to five U.S. cities to provide free educational programming designed for cancer patients and caregivers who are seeking to learn more about cancer immunotherapy and clinical trials.
Day-long endurance event starting at the U.S. Military Academy at West Point, NY, focused on cancer immunotherapy research
Cancer Immunotherapy Month in June to feature educational and awareness programming for patients, caregivers, and the public
data from four early-phase immunotherapy combination trials will be presented at the American Society for Clinical Oncology (ASCO) Annual meeting in Chicago on June 5, 2017.
Nonprofit cancer immunotherapy research organization hires pharmaceutical executive to lead its clinical trials program
Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who were previously considered untreatable. Now, discoveries made by two Cancer Research Institute scientists could help make these and other immunotherapies even more transformative for patients.
Three nonprofits partner to create powerful database that will aim to improve immunotherapy for many types of cancer.
This Saturday [Dec 3], the 58th Annual Meeting of the American Society of Hematology will begin in San Diego, where the latest advances in research for blood cancers including leukemia, lymphoma, and myeloma will be highlighted during the four days of talks and poster presentations.
Two nonprofits team up to fund immunotherapy research designed to benefit patients with an ultra-rare form of liver cancer.
New collaboration between two nonprofits focused on cancer immunotherapy aims to identify new DNA-based targets for personalized cancer treatments
Nonprofit devoted to cancer immunotherapy will honor the biotech company Amgen for its contributions to cancer immunotherapy treatment and patient education
Four leading cancer research organizations will host a conference dedicated to the latest in cancer immunotherapy.
Media are encouraged to register to attend the second annual International Cancer Immunotherapy Conference organized by the Cancer Research Institute, Association for Cancer Immunotherapy, European Academy of Tumor Immunology, and the American Association for Cancer Research.
Announcement of winners of the 2016 William B. Coley and Frederick W. Alt Awards, celebrating key scientific contributions to the fields of immunology, tumor immunology (also known as immuno-oncology), and cancer immunotherapy.
Month-long educational and awareness initiative designed increase public awareness of the potential of cancer immunotherapy to treat and potentially cure all cancers.
One-day, multi-distance ride through the Lower Hudson Valley’s breathtaking landscape to raise funds for the nonprofit Cancer Research Institute and increase awareness of the potential of immunotherapy to cure all cancers.
CRI and Inspire have partnered to launch a new cancer immunotherapy support community for patients and caregivers.
Immunotherapy is currently revolutionizing cancer treatment and, according to Axel Hoos, M.D., Ph.D., has the potential to improve patient outcomes significantly in the future. Dr. Hoos leads one of the Cancer Research Institute’s (CRI) programs—the Cancer Immunotherapy Consortium (CIC)—that played an important role in enabling early immunotherapy trials to succeed. In a paper published in Nature Reviews last week, he laid out the current immunotherapy development paradigm, as well as his strategic vision to optimize the implementation of next generation immunotherapies.
New hope now exists for patients with advanced kidney cancer. Yesterday, the FDA approved the immunotherapy drug nivolumab (Opdivo®, Bristol-Myers Squibb) to treat metastatic renal cell carcinoma (RCC)—the most common form of kidney cancer—that has failed to respond to a previous treatment. This breakthrough can be traced all the way back to the research of scientists funded by the Cancer Research Institute (CRI).
Targovax, a biotechnology company based in Oslo, has partnered with two nonprofit cancer research organizations to test its virotherapy product in early-phase combination clinical trials.
Cancer Research Institute (CRI) is proud to announce that it will be participating in the Revlon LOVE IS ON Million Dollar Challenge, which runs now through October 29, 2015.
The Cancer Research Institute announced today the winners of the 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research. This annual award recognizes the contributions of individuals, corporations, and foundations that have made a significant impact on medical research, patient care, or public education in the fields of cancer immunology and immunotherapy.
The Cancer Research Institute will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy. The award ceremony will take place at the Institute’s 29th Annual Awards Dinner on Wednesday, September 17, 2015, at The Metropolitan Club in New York City.
The Cancer Research Institute (CRI), a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.
"Immunotherapy: 5 Ways to Stop Cancer" features five 1-minute animated videos that provide a quick overview of the five most common immunotherapies in use: monoclonal antibodies, checkpoint inhibitors, cancer vaccines, adoptive cell therapy, and oncolytic viruses.
Learn the latest news in cancer immunotherapy for melanoma, lung cancer, leukemia, liver cancer, and other cancer types.
Cancer immunotherapy, which is designed to empower a patient’s own immune system to eliminate cancer cells anywhere in the body, has produced cure-like remissions in very advanced cancers, including melanoma, lung cancer, and leukemia.
The Cancer Research Institute (CRI) is proud to announce the addition of peer-to-peer advocacy, enhanced sharing functionality, and tumor type-specific information to TheAnswerToCancer.org (TheA2C), a first-of-its-kind website and online community devoted specifically to cancer immunotherapy.
The Cancer Research Institute (CRI) will host its 22nd Annual International Cancer Immunotherapy Symposium October 6-8, 2014, at The Grand Hyatt in New York City.
The Cancer Research Institute announced today the winners of the 2014 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.
CRI honors four scientists for their collective contributions to the discovery and elucidation of the PD-1 receptor pathway as a therapeutic target in cancer treatment.
Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.
Mitchell H. Gold, M.D., has been elected to the Board of Trustees of the nonprofit Cancer Research Institute. Dr. Gold is chairman, chief executive officer, and founder of Alpine Biosciences, a privately held, Seattle-based biotech company dedicated to developing the next generation of cancer immunotherapies
MedImmune, the global biologics arm of AstraZeneca, has signed a collaboration with two nonprofits, the Cancer Research Institute and Ludwig Institute for Cancer Research, to advance clinical development of cancer immunotherapy
Nonprofit pioneer in tumor immunology names recipients of 2012 scientific and lay awards celebrating outstanding contributions to advancing cancer immunotherapy.
Cancer Research Institute, Inc. announced today that it has committed more than $10 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development at research centers worldwide.
The Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the discovery and development of safe and effective immunotherapies for cancer, today announced the relaunch of the open access, online journal Cancer Immunity, the official journal of the Cancer Research Institute.
New York City's business, political, media, and philanthropy elite gathered at The Four Seasons restaurant for the "Through the Kitchen" benefit for the Cancer Research Institute, raising a record $914,000 to support cancer immunology postdoctoral research fellowships.
Cancer Research Institute awarded top score from charity ratings service Charity Navigator.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right